January 12, 2024
1 min watch
Save
VIDEO: Oral arsenic therapy ‘promising’ for acute myeloid leukemia subset
You've successfully added to your alerts. You will receive an email when new content is published.
Click Here to Manage Email Alerts
Click Here to Manage Email Alerts
We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.
SAN DIEGO — Catherine Lai, MD, MPH, spoke with Healio about a study assessing an all-oral regimen that included arsenic for patients with high-risk acute promyelocytic leukemia, a subset of acute myeloid leukemia.
The findings were presented at ASH Annual Meeting and Exposition.
“I think this is very promising,” Lai, an associate professor and physician leader of the Leukemia Clinical Research Unit at University of Pennsylvania’s Perelman Center for Advanced Medicine, said. “However, [it] needs to be confirmed in a phase 3 study but would be revolutionary if oral arsenic can replace IV arsenic as a standard of care in the future.”
Published by:
Sources/Disclosures
Collapse
Source:
Healio Interviews
Disclosures:
Lai reports consulting for AbbVie.
You've successfully added to your alerts. You will receive an email when new content is published.
Click Here to Manage Email Alerts
Click Here to Manage Email Alerts
We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.